脂肪肝、高血压与代谢综合征。
Fatty liver, hypertension, and the metabolic syndrome.
作者信息
Diehl A M
机构信息
The Johns Hopkins University, 912 Ross Building, 720 Rutland St, Baltimore, MD 21205, USA.
出版信息
Gut. 2004 Jul;53(7):923-4. doi: 10.1136/gut.2003.037309.
Abstract
The prevalence of fatty liver in non-obese non-diabetic hypertensive patients is at least twice that of the general population and may be related to increases in insulin resistance and body weight.
摘要
非肥胖、非糖尿病高血压患者的脂肪肝患病率至少是普通人群的两倍，可能与胰岛素抵抗增加和体重增加有关。
相似文献
1
Fatty liver, hypertension, and the metabolic syndrome.脂肪肝、高血压与代谢综合征。
Gut. 2004 Jul;53(7):923-4. doi: 10.1136/gut.2003.037309.
2
Hypertension and hepatic steatosis.
Curr Hypertens Rep. 2008 Jun;10(3):182-7. doi: 10.1007/s11906-008-0035-9.
3
Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease.
Diabetes Care. 2005 Jun;28(6):1518-23. doi: 10.2337/diacare.28.6.1518.
4
Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance.肝酶正常的动脉高血压患者中脂肪肝患病率增加：胰岛素抵抗的作用
Gut. 2004 Jul;53(7):1020-3. doi: 10.1136/gut.2003.027086.
5
Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.肥胖和代谢综合征作为通过超声诊断的非酒精性脂肪性肝病发生的风险因素。
Vojnosanit Pregl. 2016 Oct;73(10):910-20. doi: 10.2298/VSP150514093P.
6
Hypertension and fatty liver: guilty by association?高血压与脂肪肝：存在关联就有罪？
J Hum Hypertens. 2007 Apr;21(4):264-70. doi: 10.1038/sj.jhh.1002148. Epub 2007 Feb 1.
7
Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.系统评价：多囊卵巢综合征与代谢综合征和非酒精性脂肪性肝病的关系。
Aliment Pharmacol Ther. 2011 Apr;33(7):801-14. doi: 10.1111/j.1365-2036.2011.04579.x. Epub 2011 Jan 20.
8
The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.非肥胖非糖尿病土耳其人群中胰岛素抵抗、代谢综合征与非酒精性脂肪性肝病之间的关系：一项初步研究。
Turk J Gastroenterol. 2014 Dec;25 Suppl 1:63-8. doi: 10.5152/tjg.2014.6233.
9
Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension.原发性高血压患者的动态动脉硬化指数与非酒精性脂肪肝
Nutr Metab Cardiovasc Dis. 2013 Apr;23(4):389-93. doi: 10.1016/j.numecd.2012.05.007. Epub 2012 Jul 15.
10
Metabolic syndrome: definition, pathophysiology, and mechanisms.代谢综合征：定义、病理生理学及机制
Am Heart J. 2005 Jan;149(1):33-45. doi: 10.1016/j.ahj.2004.07.013.
引用本文的文献
1
Sex-Specific Differences in the Pathophysiology of Hypertension.高血压病理生理学中的性别差异
Biomolecules. 2025 Jan 18;15(1):143. doi: 10.3390/biom15010143.
2
Vegetable Oil-Peroxidation Product 'Hydroxynonenal' Causes Hepatocyte Injury and Steatosis via Hsp70.1 and BHMT Disorders in the Monkey Liver.植物油过氧化物产物“4-羟基壬烯醛”通过猴肝中热休克蛋白 70.1 和 BHMT 紊乱引起肝细胞损伤和脂肪变性。
Nutrients. 2023 Apr 14;15(8):1904. doi: 10.3390/nu15081904.
3
Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults.非酒精性脂肪性肝病是代谢健康的年轻成年人新发代谢综合征的先兆。
J Clin Med. 2022 Feb 11;11(4):935. doi: 10.3390/jcm11040935.
4
Black Soybean and Adzuki Bean Extracts Lower Blood Pressure by Modulating the Renin-Angiotensin System in Spontaneously Hypertensive Rats.黑豆和赤小豆提取物通过调节自发性高血压大鼠的肾素-血管紧张素系统降低血压。
Foods. 2021 Jul 6;10(7):1571. doi: 10.3390/foods10071571.
5
Effects of earthworm extract on the lipid profile and fatty liver induced by a high-fat diet in guinea pigs.蚯蚓提取物对高脂饮食诱导的豚鼠血脂谱和脂肪肝的影响。
Ann Transl Med. 2021 Feb;9(4):292. doi: 10.21037/atm-20-5362.
6
Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.非酒精性脂肪性肝病和代谢相关脂肪性肝病的结局：一项基于社区的前瞻性队列研究结果。
PLoS One. 2021 Feb 3;16(2):e0245762. doi: 10.1371/journal.pone.0245762. eCollection 2021.
7
Changes in Body Weight and Concurrent Changes in Cardiovascular Risk Profiles in Community Residents in Japan: the Hisayama Study.日本社区居民体重变化与心血管风险特征的同期变化：日山研究。
J Atheroscler Thromb. 2022 Feb 1;29(2):252-267. doi: 10.5551/jat.59394. Epub 2021 Jan 17.
8
Malabaricone C as Natural Sphingomyelin Synthase Inhibitor against Diet-Induced Obesity and Its Lipid Metabolism in Mice.马拉巴酮C作为天然鞘磷脂合酶抑制剂对小鼠饮食诱导肥胖及其脂质代谢的影响
ACS Med Chem Lett. 2019 Jul 3;10(8):1154-1158. doi: 10.1021/acsmedchemlett.9b00171. eCollection 2019 Aug 8.
9
The anti-inflammatory potential of diet and nonalcoholic fatty liver disease: the ATTICA study.饮食与非酒精性脂肪性肝病的抗炎潜力：阿提卡研究
Therap Adv Gastroenterol. 2019 Jun 23;12:1756284819858039. doi: 10.1177/1756284819858039. eCollection 2019.
10
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease.氧化应激在非酒精性脂肪性肝病发病机制中的作用。
Oxid Med Cell Longev. 2018 Jun 11;2018:9547613. doi: 10.1155/2018/9547613. eCollection 2018.
本文引用的文献
1
Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance.肝酶正常的动脉高血压患者中脂肪肝患病率增加：胰岛素抵抗的作用
Gut. 2004 Jul;53(7):1020-3. doi: 10.1136/gut.2003.027086.
2
Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study.脂肪肝患者的预后——一项基于登记处的队列研究。
Hepatogastroenterology. 2003 Nov-Dec;50(54):2101-4.
3
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.非酒精性脂肪性肝病的自然史：一项临床组织病理学研究。
Am J Gastroenterol. 2003 Sep;98(9):2042-7. doi: 10.1111/j.1572-0241.2003.07659.x.
4
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.高体重指数是慢性丙型肝炎患者对抗病毒治疗无应答的独立危险因素。
Hepatology. 2003 Sep;38(3):639-44. doi: 10.1053/jhep.2003.50350.
5
Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions.胰岛素抵抗作为一种促炎状态：机制、介质及治疗干预措施
Curr Drug Targets. 2003 Aug;4(6):487-92. doi: 10.2174/1389450033490920.
6
The relationship of obesity to the metabolic syndrome.
Int J Clin Pract Suppl. 2003 Mar(134):18-27.
7
Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.肝脂肪变性是慢性丙型肝炎病毒感染患者发生肝细胞癌的一个危险因素。
Cancer. 2003 Jun 15;97(12):3036-43. doi: 10.1002/cncr.11427.
8
Current concepts of cardiovascular diseases in diabetes mellitus.糖尿病中心血管疾病的当前概念
Int J Cardiol. 2003 Jun;89(2-3):123-34. doi: 10.1016/s0167-5273(02)00510-7.
9
Current best treatment for non-alcoholic fatty liver disease.非酒精性脂肪性肝病的当前最佳治疗方法。
Expert Opin Pharmacother. 2003 May;4(5):611-23. doi: 10.1517/14656566.4.5.611.
10
Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study.适度饮酒对慢性丙型肝炎患者组织学活性和纤维化的影响以及脂肪变性的具体影响：一项前瞻性研究。
Aliment Pharmacol Ther. 2003 Apr;17(8):1031-7. doi: 10.1046/j.1365-2036.2003.01546.x.
Zotero 插件